Bio-Thera and STADA will collaborate on biosimilar tocilizumab for treating inflammatory disorders.

Bio-Thera and STADA have announced an extension of their biosimilars partnership to include tocilizumab, an immunomodulatory monoclonal antibody that targets the interleukin-6 receptor. Tocilizumab is used to treat various inflammatory and autoimmune conditions. This agreement allows Bio-Thera to expand their portfolio with this critical drug, further solidifying their collaboration with STADA in the biosimilars market.